BC Week In Review | Jun 22, 2018
Financial News

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated....
BC Extra | Jun 19, 2018
Financial News

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated....
BC Week In Review | Jul 7, 2017
Clinical News

AZ reports data from Phase I BLOOM trial of Tagrisso in NSCLC

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from 21 evaluable EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases in the Phase I BLOOM trial showing that oral Tagrisso osimertinib (AZD9291) led to an...
BC Week In Review | Jun 1, 2015
Clinical News

AZD3759: Preliminary Phase I data

Preliminary data from 2 evaluable patients with EGFR mutation-positive NSCLC with brain metastasis in an open-label, dose-escalation, international Phase I trial showed that twice-daily 50 and 100 mg AZD3759 led to 1 unconfirmed partial response...
Items per page:
1 - 4 of 4